Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

August 27, 2025

Study Completion Date

August 27, 2025

Conditions
Dravet SyndromeEpilepsyChildhoodEpileptic EncephalopathyPediatric Epilepsy
Interventions
DRUG

Stiripentol capsule (Diacomit®)

Single oral administration of 1,000 mg stiripentol (2 × 500 mg capsules) at the end of breakfast.

DRUG

Stiripentol oral suspension (Diacomit®)

Single oral administration of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL) at the end of breakfast.

Trial Locations (2)

38610

EUROFINS OPTIMED, 1 rue des Essarts, Gières

60200

3 Chemin d'Armancourt, Compiègne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biocodex

INDUSTRY